ClinicalTrials.gg
CompletedNCT00744848Updated Aug 6, 2013Results posted

Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy

A Phase 3 interventional study of Bupivacaine HCl and SKY0402 in Hemorrhoids, sponsored by Pacira Pharmaceuticals, Inc. Completed at 20 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-06.

Sponsored by Pacira Pharmaceuticals, Inc · Phase 3, Interventional, and Supportive care

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
204
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 33 studies in Hemorrhoids with a site in United States — 9 open to participants now, 9 under way, none of them phase 3. Hemorrhoids · United States.

Enrollment
3rd of 28
204 · median 83
Started
2008
with 1 other
Phase 3
2 of 33
none open now
Registered
4th of 33
by date

Among the 33 studies in Hemorrhoids with a site in United States, this one is the 3rd largest by enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2008, is one of 2 in phase 3, and was the 4th registered.

Hemorrhoids

239 studies on the registry are indexed under Hemorrhoids; 73 are open to participants now.

Browse Hemorrhoids studies →

Open to participants now

9 of the 33 studies in Hemorrhoids with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 38 Hemorrhoids studies recruiting now, 15 (39%) set no upper age limit and 11 (29%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 33 studies in Hemorrhoids with a site in United States, or all of them as a file.
02

Study summary

Effective postoperative pain control to promote improved healing, faster patient mobilization, shortened hospital stays, and reduced healthcare costs.

Read the detailed description

Effective postoperative pain control is a critical element in patient recovery, as the majority of patients may experience significant pain, particularly in the first few days following surgery. Appropriate postoperative pain management contributes to improved healing, faster patient mobilization, shortened hospital stays, and reduced healthcare costs.

03

Conditions studied

  • Hemorrhoids

Browse trials for

Keywords

  • hemorrhoids
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female equal or greater than 18 years of age at Screening
  • Female subjects: , surgically sterile, or willing to use acceptable means of for at least 30 days after surgery, nonheterosexual lifestyle, or strictly monogamous relationship with a partner who has had a vasectomy.
  • Scheduled to undergo 2-or3-column excisional hemorrhoidectomy
  • American Society of Anesthesiology (ASA) Physical Class 1-4
  • Able and willing to complete with all study visits and procedures
  • Able to speak, read, and understand the language of all study forms and instruments used for collecting subject-reported outcomes to provide accurate study assessments
  • Willing and capable of provide written .

Exclusion criteria

Exclusion Criteria:

  • Pregnant, nursing or planning to become pregnant during the study period
  • Use of any long-acting opioid medication within 3 days of surgery or any opioid medication with 24 hours of surgery.
  • Concurrent painful physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain not strictly related to the procedure or that may interfere with study assessments.
  • Single-column hemorrhoidectomy
  • Body weight less than 50 kg (110 pounds)
  • History of or idiosyncratic reaction to amide-type local anesthetics, opioid medication, or any ingredient of the medications administered in this study (e.g., sulfites in Marcaine with epinephrine)
  • to epinephrine
  • contraindication to any of the pain-control agents planned for postoperative use
  • Administration of an drug within 30 days or 5 elimination half-lives of such investigational drug prior to study drug administration
  • History of, known addiction, or abuse of illicit drugs, prescription medicines or alcohol within the past 2 years.
  • Uncontrolled anxiety schizophrenic, or other psychiatric disorder that may interfere with study assessments or compliance.
  • Significant medical conditions or laboratory results that indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial.
  • Any event or condition uncovered during surgery
  • A cumulative incision length less than 3 cm
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Investigator)
Enrollment
204 participants (actual)

Study arms

  • Active comparator
    Bupivacaine HCl

    100 mg Bupivacaine HCl (e.g., Marcaine with epinephrine 1:200,000) is the reference-listed drug for bupivacaine and contains the same active, local anesthetic as SKY0402. A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration.

    Drug: Bupivacaine HCl

  • Other
    SKY0402

    300 mg SKY0402 in a 40-mL injection volume. A single dose of study drug was administered intraoperatively (at the end of surgery) via local infiltration.

    Drug: SKY0402

Interventions

  • 100 mg Bupivacaine HCl

    Also known as: Marcaine with epinephrine 1:200,000

  • Single administration 300 mg SKY0402 in a 40-mL injection volume

    Also known as: DepoBupivacaine

06

What researchers measure

Primary outcomes

  1. Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores

    To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question, "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?"

    Time frame: through 96 hours

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs) Through Day 3 and Serious Adverse Events (SAEs) Through Day 30

    Time frame: through day 30

07

Results

Posted Aug 6, 2013

Participant flow

Participant flow — Overall Study
MilestoneBupivacaine HClSKY0402
Started103101
Completed103101
Not completed00

Outcome measures

PrimaryArea Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores

To assess pain intensity at rest (NRS-R), the subject was to assume a resting position that did not exacerbate his or her postoperative pain. The subject was to rest in this position for at least 5 minutes before responding to the following question, "On a scale of 0 to 10, where 0=no pain and 10=worst possible pain, how much pain are you having right now?"

Time frame:
through 96 hours
Reported as:
Mean · Units on a scale*hours
Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores
Units on a scale*hoursBupivacaine HClSKY0402
Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores359 ± 194396 ± 213
SecondaryNumber of Participants With Adverse Events (AEs) Through Day 3 and Serious Adverse Events (SAEs) Through Day 30
Time frame:
through day 30

Results for this outcome have not been posted.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bupivacaine HCl—1/103 (1%)65/103 (63.1%)
SKY0402—1/101 (1%)67/101 (66.3%)
Most frequent serious events
Most frequent serious events
EventBupivacaine HClSKY0402
Chronic Postop PainGeneral disorders0/1031/101
Fecal ImpactionGastrointestinal disorders0/1031/101
Bleeding UlcerGastrointestinal disorders1/1030/101
Most frequent other events
Most frequent other events
EventBupivacaine HClSKY0402
NauseaGastrointestinal disorders32/10338/101
ConstipationGastrointestinal disorders12/10316/101
VomitingGastrointestinal disorders9/10316/101
PyrexiaGeneral disorders0/1038/101
HeadacheNervous system disorders7/1033/101
FlatulenceGastrointestinal disorders2/1035/101
Abdominal PainGastrointestinal disorders0/1035/101
PruritisSkin and subcutaneous tissue disorders4/1035/101
Urinary RetentionRenal and urinary disorders0/1035/101

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Bupivacaine HClSKY0402Total
<=18 years000
Between 18 and 65 years9495189
>=65 years9615
Age Continuous
Age Continuous(years)Bupivacaine HClSKY0402Total
Mean49 ± 11.650.2 ± 1149.6 ± 11.3
Sex: Female, Male
Sex: Female, Male(Participants)Bupivacaine HClSKY0402Total
Female504898
Male5353106
Region of Enrollment
Region of Enrollment(participants)Bupivacaine HClSKY0402Total
United States103101204
08

Study locations

20 sites
  • West Alabama Research Inc.
    Birmingham, Alabama 35209, United States
  • Drug Research and Analysis Corporation
    Montgomery, Alabama 36106, United States
  • Lotus Clinical Research - Huntington Memorial Hospital
    Pasadena, California 91105, United States
  • Accurate Clinical Trials
    San Clemente, California 92672, United States
  • UCSD Medical Center
    San Diego, California 92121, United States
  • Colon and Rectal Disease Center
    Orlando, Florida 32804, United States
  • University of Illinois
    Springfield, Illinois 62708-0787, United States
  • Indiana University - Wishard Memorial Hospital
    Indianapolis, Indiana 46202, United States
  • University of Louisville
    Louisville, Kentucky 40202, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • CTMG, Inc. - Pitt Medical Center
    Greenville, North Carolina 27834, United States
  • Univ. Hospitals of Cleveland, Case Medical Center
    Cleveland, Ohio 44106, United States
  • Holston Medical Group
    Kingsport, Tennessee 37660, United States
  • Research Concepts, Ltd
    Bellaire, Texas 77401, United States
  • Medical Center Ambulatory Surgery Center
    Houston, Texas 77054, United States
  • The Women's Hospital of Texas
    Houston, Texas 77054, United States
  • Roland Saenz
    San Antonio, Texas 78205, United States
  • Multicare Health System
    Tacoma, Washington 98405, United States
09

References and documents

Publications

  • Dasta J, Ramamoorthy S, Patou G, Sinatra R. Bupivacaine liposome injectable suspension compared with bupivacaine HCl for the reduction of opioid burden in the postsurgical setting. Curr Med Res Opin. 2012 Oct;28(10):1609-15. doi: 10.1185/03007995.2012.721760. Epub 2012 Sep 3. PubMed 22900785 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Feb 2009 and a completion of Feb 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 4 years 6 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2008
First posted
Sep 1, 2008
Start
Aug 2008
Primary completionActual
Feb 2009
CompletionActual
Feb 2009
Results delay requested
Aug 25, 2010
Results first posted
Aug 6, 2013
Last update
Aug 6, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00744848
Responsible party
Sponsor
First posted
Sep 1, 2008
Start date
Aug 2008
Primary completion
Feb 2009
Completion
Feb 2009
Results posted
Aug 6, 2013
Last update
Aug 6, 2013

Study contacts

Kay Warnott, RN, ACN-P
study director · Pacira Pharmaceuticals, Inc

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bupivacaine

Start the discussion